Alzheimer’s Disease & Dementia
Public health strategies for preventing dementia should target socioeconomic gaps to reduce health disparities and protect the disadvantaged.
The researchers encouraged clinicians not to rely solely on medication to treat midlife anxiety, as benzodiazepines have been shown to increase mortality in certain groups; they pointed to talk therapy, meditation, and mindfulness-based interventions as possible considerations.
Multimarker inflammatory biosignatures are expected to facilitate diagnosis and predict treatment outcomes for various central nervous system disorders, particularly Alzheimer disease and major depressive disorder.
Clinicians should take depression into careful consideration when treating patients with Alzheimer dementia, as the two conditions combined may predispose patients to cardiovascular disease more than either condition alone.
These findings indicate that anxiety may be a risk factor for late-life dementia, excluding anxiety that is related to prodromal cognitive decline.
These results suggest that antipsychotic exposure has no impact on relative mortality.
These data support the importance of TBI preventative measures and proper management strategies for subsequent dementia.
The findings also suggested that more a more recent diagnosis of psychosis was a greater predictor of the development of dementia, as opposed to cases where patients had been living with psychotic disorder diagnoses for 10 years or more.
Patients with a phonemic advantage at baseline should be followed more closely with a higher index of suspicion for progression to Alzheimer disease.
Investigators evaluated CSF Aβ1-42 levels obtained from individuals who presented no signs of cognitive dysfunction at enrollment and estimated the proximity of participants' age to their parents' age of AD symptom onset.
Spouses who are affected by dementia may benefit from an at-home dyadic, relationship-focused psychoeducational intervention.
These findings support the recognition of alcohol use disorders as a major risk factor for all dementia types.
There are a handful of biomarkers that offer potential value for predicting the risk for development of MCI symptoms from AD symptoms.
The researchers noted that automated tests should not be used alone, but should instead be used as part of a comprehensive evaluation that must include clinical judgment and involve traditional assessor-guided cognitive batteries.
Dementia risk was associated with neither proton pump inhibitor exposure nor duration of use.
Low memory scores are not a good tool for measure early Alzheimer's disease in people without dementia.
Traumatic brain injury is a significant burden on the US health system and is a contributing factor in one-third of all injury-related deaths.
Obstructive sleep apnea and sleep-disordered breathing are associated with amyloid deposition, biomarkers for Alzheimer's disease.
It may be possible to grow old without developing Alzheimer's disease pathology.
More research is needed to assess the effect of modifying sleep on the brain.
Three promising areas of future research in cognitive decline are blood pressure, cognitive training, and physical exercise.
Dual task gait training is predictive of clinical progression of mild cognitive impairment leading to dementia.
Depressive symptoms likely do not increase the risk of dementia.
Neuropsychiatric symptoms, specifically sleep behavior and irritability, may be an early symptom of Alzheimer's dementia.
Serum IL-6 levels may serve as biomarkers for Alzheimer's disease.
Alzheimer's disease risk increases for hospitalized patients with shorter than a 5-year window.
A history of 2 or more vascular risk factors was associated with a significantly higher rate of amyloid deposits on PET scans at last visit.
Early occult hippocampal hyperexcitability may contribute to the pathogenesis of Alzheimer's disease.
Women who use hormone therapy after menopause may not have a lower risk of developing Alzheimer's disease.
As stroke is often detrimental for individuals with AD, these results warrant caution in BZDR use in this vulnerable population.
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Sertraline Effective for Treating Depression in Vascular Cognitive Impairment
- Hospitalization Rates in Schizophrenia—Lurasidone vs Quetiapine
- Ketamine-Induced Dissociative Symptoms Predict Antidepressant Response
- First Nonopioid Drug Approved for Managing Opioid Withdrawal Symptoms
- Psychopathology of Adults Affected by Pre- and Perinatal Factors, Family Functioning
- Video Games and Exercise as Alternative Therapies for ADHD
- How Parents Can Enhance Autism Treatment: Use of Intervention Strategies at Home
- Electroconvulsive Therapy Effective in Children With Autism
- Comorbid Autism Spectrum Disorder and OCD: Challenges in Diagnosis and Treatment
- The Cutting Edge of Schizophrenia Research: VR as Treatment for Psychosis
- HIV Viral Suppression Rates in Psychiatric Inpatients With Comorbid Substance Use Disorders
- Greater Wealth Associated With Lower Risk for Dementia in English Study
- Social Hygiene: Screening for Social Media Addiction in Adolescent Patients
- Effects of Depressive Symptoms on Cognition, Markers of Brain Aging
- Substance Abuse and Primary Psychosis: A Closer Look